seed
Stage
About
RyboDyn develops AI-driven immunotherapies by identifying therapeutic targets from the dark proteome, using proprietary RNA sequencing and AI models to discover proteins encoded by previously considered non-coding regions of the genome.
Explore RyboDyn's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.